HyQvia Needs Provider, Patient Education, Not Population Restrictions, Panel Says
Executive Summary
CBER’s Blood Products Advisory Committee votes in favor of communication strategies to mitigate the risks of Baxter’s primary immune deficiency treatment but not to monitor for possible adverse events associated with long-term exposure.